US Patent 9,265,758: Lomitapide Dose-Escalation Claims, Patent Scope, and Generic-Entry Risk

US Patent 9,265,758 protects a clinical dosing method for lomitapide, an oral microsomal triglyceride transfer protein inhibitor used to treat homozygous familial hypercholesterolemia. The patent does not primarily claim the lomitapide molecule, its basic composition, or a formulation. Its central rights are method-of-treatment claims requiring step-wise dose escalation over defined dose ranges and treatment intervals.

The commercial significance is narrower than a composition patent but potentially material for an ANDA applicant whose proposed labeling follows the patented titration regimen. The principal validity issues are written description, enablement, obviousness, claim construction, and whether a proposed generic label induces performance of the claimed regimen.

What drug and treatment method does US Patent 9,265,758 cover?

The claimed MTP inhibitor is lomitapide, also known as BMS-201038 and marketed in the United States as Juxtapid. The claims cover treatment of hyperlipidemia or hypercholesterolemia using escalating daily doses rather than immediate administration of a higher starting dose.

The claimed regimen has these core elements:

Claim element	Required scope
Patient condition	Hyperlipidemia or hypercholesterolemia
Active ingredient	Lomitapide, a pharmaceutically acceptable salt, or piperidine N-oxide
Route	Oral administration is expressly covered by dependent claim 5
First dose	About 2 to about 13 mg/day
Second dose	About 5 to about 30 mg/day
Third dose	About 10 to about 50 mg/day
Dose sequencing	At least three step-wise, increasing dose levels
Duration	Approximately 1 to 5 weeks under claim 1; 1 to 4 weeks under claims 7 and 9
Additional escalation	Fourth dose level and maximum dose level under claims 6, 8, and 10
Clinical result	Reduced steatorrhea and/or hepatic fat under claims 7 and 9

The broadest independent claim is claim 1. Claims 7 and 9 add safety or tolerability outcomes, making them narrower and potentially more difficult to prove in litigation because the patentee must establish the claimed clinical result.

How broad is the independent claim scope?

Claim 1 requires a specific treatment sequence, but it does not require every commercially used lomitapide dose. The claim is potentially infringed when a physician administers:

A first daily dose within 2-13 mg;
A higher second daily dose within 5-30 mg;
A higher third daily dose within 10-50 mg; and
Each dose for approximately one to five weeks.

The ranges overlap substantially. A typical 5 mg, 10 mg, and 20 mg escalation sequence falls within the literal numerical ranges. A 5 mg, 10 mg, 20 mg, 40 mg, and 60 mg sequence also falls within claims 6, 8, or 10 if the duration and maximum-dose requirements are satisfied.

The phrase “step-wise, increasing” imposes an ordering requirement. A regimen of 5 mg followed by 5 mg again would not satisfy the increasing-dose limitation. A regimen beginning at 20 mg may avoid claim 1 because the first dose must be no more than about 13 mg, although infringement analysis would depend on the meaning of “about” and the exact accused regimen.

The term “about” creates a factual range rather than an unlimited tolerance. Its construction would likely depend on the specification, prosecution history, clinical dosing data, and the technical meaning of dose approximation in the field.

What do claims 2 through 10 add?

Claim	Added limitation	Commercial or litigation significance
1	Three escalating dose ranges, 1-5 weeks per level	Broadest principal method claim
2	Severe hypercholesterolemia	Narrows patient population
3	At least 15% reduction in specified lipid or apolipoprotein markers	Requires clinical outcome
4	At least 25% reduction in specified markers	Narrower efficacy claim
5	Oral administration	Aligns with Juxtapid use
6	Fourth dose level	Covers extended escalation
7	Three escalating doses up to a maximum; 1-4 weeks; reduced steatorrhea versus 25 mg/day starting dose	Adds comparative tolerability limitation
8	Fourth dose of 20-60 mg/day and maximum dose of 30-75 mg/day	Targets higher-dose titration
9	Reduced steatorrhea and/or hepatic fat	Requires a safety or hepatic outcome
10	Fourth dose and maximum dose ranges	Narrows claim 9 to specified escalation

Claims 3 and 4 are outcome-defined claims. They do not require a particular percentage reduction in every listed biomarker. Reduction in one listed parameter may be sufficient, provided the claim’s other limitations are met.

Claims 7 and 9 introduce potential proof complications. A patentee would need to show that the accused regimen produces the specified reduction in steatorrhea or hepatic fat, or that the clinical result is an inherent consequence of practicing the claimed method.

What patent protects the lomitapide molecule itself?

US Patent 9,265,758 is not the principal molecule patent for lomitapide. Its claims are directed to treatment methods and dose escalation.

Lomitapide’s broader patent estate has historically included several categories:

Patent category	Typical protected subject matter	Relevance to generic entry
Composition of matter	Lomitapide and related compounds	Usually the strongest exclusionary right
Salt and crystal forms	Pharmaceutical salts, polymorphs, or solid forms	Can restrict API or finished-product manufacture
Formulations	Oral dosage forms and excipient combinations	Relevant to product composition
Treatment methods	Hypercholesterolemia and HoFH treatment	Relevant to labeling and induced infringement
Dose escalation	Starting dose, titration, tolerability, hepatic-fat reduction	Relevant to proposed generic labeling
Manufacturing	Synthesis, purification, or intermediate preparation	Relevant to API suppliers and paragraph IV risk

The expiration of a molecule patent does not eliminate later method, formulation, or manufacturing patents. A generic applicant must assess each listed patent independently.

When does US Patent 9,265,758 lose exclusivity?

The patent issued on February 23, 2016. Its priority chain reaches back to 2008, producing a nominal patent-term endpoint in 2029 under the standard 20-year term measured from the earliest effective nonprovisional filing date. The enforceable term must be determined from the patent’s continuity data, terminal disclaimers, patent-term adjustment, and any applicable patent-term extension.

Event	Date
Earliest priority period	2008
US patent issued	February 23, 2016
Nominal term endpoint	2029
FDA regulatory exclusivity	Separate from patent term
Generic entry date	Determined by Orange Book certifications, litigation, settlement, and court judgment

Patent expiration does not automatically authorize a generic launch if another listed patent remains enforceable. Conversely, an unexpired method patent may have limited practical value if the generic label omits the patented indication or titration instructions and the product can be prescribed for an unpatented use.

What is the Orange Book status of US Patent 9,265,758?

The relevant FDA product is NDA 203858 for Juxtapid. The Orange Book determines whether a patent is listed against that NDA and whether it is categorized as a drug-substance, drug-product, or method-of-use patent. A method-of-use listing generally appears with a use code describing the covered indication or treatment method.[2]

For an ANDA applicant, the key questions are:

Whether US 9,265,758 is listed against NDA 203858;
The associated use code;
Whether the proposed generic labeling overlaps that use code;
Whether the applicant files a Paragraph IV certification;
Whether the NDA holder files suit within 45 days; and
Whether a 30-month stay or court order delays approval.

A method patent may not block an ANDA if the proposed label uses a valid section viii statement and carves out the patented method. That strategy depends on whether the remaining label is commercially viable and whether the FDA considers the proposed labeling adequate for safe use.

What Paragraph IV risks does this patent create?

A Paragraph IV challenge would likely argue that the asserted claims are invalid, unenforceable, or not infringed. The principal arguments would be:

Obviousness

A challenger could combine:

Earlier lomitapide clinical studies;
Known dose-escalation practices;
The FDA-approved starting-dose approach;
Data linking high starting doses to gastrointestinal adverse events; and
Routine clinical efforts to reduce steatorrhea or hepatic fat.

The patentee would respond that the claimed sequence produced an unexpected tolerability benefit and provided a clinically meaningful solution to known MTP-inhibitor toxicity.

Written description and enablement

The claims cover broad overlapping dose ranges, multiple treatment intervals, fourth-dose options, and maximum doses extending to 75 mg/day. A challenger could argue that the specification does not adequately support the full breadth of those combinations or enable every claimed regimen without undue experimentation.

Indefiniteness

Potentially contested terms include:

“About”;
“Step-wise, increasing”;
“Effective amount”;
“Reduced steatorrhea”;
“Reduced hepatic fat”; and
“Compared to control levels.”

The strongest indefiniteness arguments would focus on undefined comparison standards and the breadth of “about” in the dose ranges.

Infringement

Direct infringement requires performance of every method step by a patient or healthcare provider. Induced-infringement exposure could arise from a generic label, prescribing information, physician instructions, or promotional material that directs the claimed titration schedule.

A label that begins at 5 mg and increases at regular intervals may create greater risk than a label that omits the patented method and leaves titration to physician judgment. The practical assessment depends on the exact proposed label.

How does this patent compare with formulation and composition patents?

US 9,265,758 is generally weaker than a valid composition-of-matter patent in terms of breadth and enforcement leverage.

Patent type	Scope	Typical strength
Composition patent	Covers the active molecule across uses and formulations	Highest
Salt or polymorph patent	Covers defined chemical or solid-state forms	High if the commercial product uses the claimed form
Formulation patent	Covers a dosage form or excipient system	Moderate to high
Manufacturing patent	Covers a process or intermediate	Variable
Dose-escalation method patent	Covers clinical administration sequence	Narrower and fact-intensive
Biomarker or outcome method patent	Covers treatment producing a defined result	Narrow but potentially valuable

The patent’s value increases if the FDA-approved label requires or strongly recommends the claimed titration sequence. Its value decreases if a generic can use a non-infringing label while maintaining adequate instructions for safe administration.

What regulatory and commercial barriers affect generic launch?

Lomitapide is approved for HoFH, a rare disease with a restricted commercial market. The product carries significant safety-management requirements, including hepatic monitoring and risk management associated with liver toxicity. The FDA prescribing information recommends a low starting dose followed by gradual titration, with a maximum daily dose of 60 mg for the approved product.[1]

A generic applicant faces several non-patent barriers:

Limited patient population;
Complex safety monitoring;
Potentially restricted distribution requirements;
Physician familiarity with the branded titration protocol;
Need for bioequivalence at multiple strengths;
API and formulation controls;
Potential difficulty obtaining commercial scale; and
Method-of-use patent exposure.

The absence of a broad molecule patent does not guarantee rapid generic substitution. A restricted HoFH market can support a targeted litigation strategy even where expected generic revenue is modest.

Which companies compete with lomitapide?

Lomitapide competes with other therapies for severe or homozygous familial hypercholesterolemia, including:

Evinacumab, marketed as Evkeeza;
LDL apheresis;
PCSK9-directed therapies in appropriate patients;
Inclisiran and monoclonal-antibody PCSK9 therapies;
Statins and ezetimibe, although their effect may be limited in HoFH;
Bempedoic-acid-based therapy in broader hypercholesterolemia populations; and
Gene- and RNA-based approaches under development.

Lomitapide’s commercial position depends on its LDL-lowering efficacy, hepatic safety profile, tolerability, monitoring burden, and payer access. A generic entrant would compete against both branded Juxtapid and alternative HoFH therapies, not merely against the patented product.

What is the overall patent strength of US 9,265,758?

The patent has meaningful but bounded strength.

Strengths

Claims a clinically specific titration sequence;
Covers commonly used low-to-high lomitapide dosing patterns;
Addresses a known tolerability problem;
Includes claims directed to reduced steatorrhea and hepatic fat;
Can create induced-infringement risk through generic labeling.

Weaknesses

It is a method patent rather than a composition patent;
Its protection depends on the exact dosing instructions;
Several limitations use broad or potentially disputed terms;
Clinical-outcome claims may be difficult to prove;
A generic may seek a label carve-out;
Obviousness arguments can rely on dose escalation and known adverse-event management.

The highest-risk scenario for a generic applicant is a label that expressly instructs 5 mg initiation followed by sequential increases over one- to four-week intervals toward 40-60 mg/day. The lower-risk scenario is a label that excludes the patented use or adopts a dosing protocol outside the claimed sequence, subject to FDA safety requirements and induced-infringement principles.

Key Takeaways

US 9,265,758 claims dose-escalation methods for lomitapide, not the basic lomitapide molecule.
The principal protected regimen uses at least three increasing daily dose levels within defined ranges.
Claims 7-10 focus on reduced steatorrhea and hepatic fat and are narrower than claim 1.
The patent issued February 23, 2016, with a nominal term extending into 2029.
Orange Book listing, use-code scope, and the exact generic label determine Paragraph IV exposure.
A section viii carve-out may reduce risk if the patented titration method can be removed without making the label inadequate.
The patent is commercially relevant but materially narrower and more litigation-sensitive than a composition-of-matter patent.
Generic launch risk depends on the full Juxtapid patent estate, not US 9,265,758 alone.

FAQs About US Patent 9,265,758 and Lomitapide Exclusivity

Does US Patent 9,265,758 cover Juxtapid tablets themselves?

No. The claims primarily cover administration of lomitapide using defined escalating dose levels and treatment intervals. They do not broadly claim every Juxtapid tablet or every lomitapide formulation.

Can a generic launch if it avoids the patented dose-escalation schedule?

Potentially. A generic would still need to address other Orange Book-listed patents, FDA labeling requirements, and any induced-infringement risk created by its proposed instructions.

Does the patent cover a 5 mg, 10 mg, 20 mg, 40 mg, and 60 mg regimen?

That regimen can fall within the patent’s claim ranges if the dose levels increase sequentially, are administered for the required intervals, and satisfy the applicable fourth-dose and maximum-dose limitations.

Why are claims directed to steatorrhea commercially important?

Steatorrhea is a recognized tolerability problem associated with MTP inhibition. Claims linking dose escalation to reduced steatorrhea can reach a clinically important use even when the underlying drug compound is no longer protected by a basic composition patent.

Does patent expiration end FDA exclusivity for lomitapide?

No. Patent expiration and FDA regulatory exclusivity are separate rights. Approval timing also depends on ANDA certifications, litigation, settlement terms, orphan-drug exclusivity, and any other listed patents.

References

U.S. Food and Drug Administration. (2023). Juxtapid (lomitapide mesylate) prescribing information.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Patent No. 9,265,758. (2016). Methods for treating hyperlipidemia. United States Patent and Trademark Office.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1725234	⤷ Start Trial	CA 2014 00002	Denmark	⤷ Start Trial
European Patent Office	1725234	⤷ Start Trial	C300634	Netherlands	⤷ Start Trial
European Patent Office	1725234	⤷ Start Trial	PA2014001	Lithuania	⤷ Start Trial
European Patent Office	1725234	⤷ Start Trial	C20140001 00107	Estonia	⤷ Start Trial
European Patent Office	1725234	⤷ Start Trial	14C0003	France	⤷ Start Trial
European Patent Office	1725234	⤷ Start Trial	1490006-2	Sweden	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,265,758

Summary for Patent: 9,265,758